HepVu has launched new interactive maps illustrating state-level estimates of people living with hepatitis C across the United States. The maps highlight a concentration of infections in some states most impacted by the opioid epidemic. Published in JAMA Network Open, the data reveal an estimated 2.3 million people living with hepatitis C infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.
“We still have more than 2 million people living with hepatitis C at a time when ending this epidemic is possible,” says Dr. Patrick Sullivan, professor of epidemiology at Emory University’s Rollins School of Public Health and principal scientist for AIDSVu.
“Hundreds of thousands of Americans have been cured of hepatitis C with newly available treatments, yet new hepatitis C infections have nearly tripled in recent years as a consequence of increasing injection drug use associated with the opioid epidemic. At the same time, many older Americans, who have been living with hepatitis C for decades, still remain undiagnosed and untreated. Halting the hepatitis C epidemic requires a commitment across the nation to diagnose and cure people living with the virus and stop new infections before they erode our significant progress.”
Three-fourths of Americans living with hepatitis C are Baby Boomers (those born between 1945 and 1965). However, the largest increases in hepatitis C infections over the last decade have been among individuals less than 40 years old and particularly among persons who inject drugs.
“Hepatitis C and other infectious diseases are often-overlooked consequences of America’s opioid crisis,” says Dr. Eli Rosenberg, associate professor of epidemiology and biostatistics, University at Albany School of Public Health, State University of New York. “Our analysis helps to pinpoint the concentration of the disease geographically and shows the burden of hepatitis C is greater in places highly affected by the opioid epidemic.”
Key findings include:
“One of the most critical challenges in our national response to viral hepatitis is limited data that we can use to understand and monitor the epidemic,” says Dr. Sullivan. “Accurate estimates of the burden of hepatitis C infection in each state are essential to inform policy, programmatic, and resource planning for elimination strategies across the U.S. By mapping hepatitis C in the U.S., HepVu seeks to provide a comprehensive picture of the disease’s impact on states to inform researchers and public health decision-makers’ prevention and care efforts.”
HepVu is a Powered By AIDSVu project presented by Emory University Rollins School of Public Health in partnership with Gilead Sciences, Inc. State-level hepatitis C prevalence estimates on HepVu can be viewed alongside social determinants of health and data related to the opioid epidemic, including opioid prescription rate, narcotic overdose mortality rate and pain reliever misuse prevalence. HepVu also visualizes data on hepatitis C-related mortality (2016) obtained from the Centers for Disease Control and Prevention’s (CDC) WONDER Online Database System. Additionally, HepVu offers downloadable datasets for researchers and health departments to utilize in their own analyses, infographics on hepatitis B and C, and state-specific factsheets.
The state-level hepatitis C prevalence estimates displayed on HepVu are produced by the Emory University Coalition for Applied Modeling for Prevention (CAMP) project with researchers from the University of Albany and developed with CDC. Findings were published in the peer-reviewed Journal of the American Medical Association (JAMA) Network Open in an article titled, “Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2013 – 2016”.
The new data are derived using an updated approach to the previously published methodology for 2010 state-specific hepatitis C prevalence estimation that reflects current changes to the epidemic. To estimate state-level hepatitis C prevalence, researchers analyzed blood test results from the nationally representative National Health and Nutrition Examination Survey (NHANES) and vital statistics data from 2013 through 2016, and incorporated data on hepatitis C-related deaths and narcotic overdose deaths. The researchers also estimated the number of hepatitis C infections among populations not included in NHANES, including incarcerated, unsheltered homeless, and nursing home resident populations. For more information on the data methods, please visit HepVu.org.